National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 2255-2256 [06-308]

Download as PDF Federal Register / Vol. 71, No. 9 / Friday, January 13, 2006 / Notices (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: January 5, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–313 Filed 1–12–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Complementary and Alternative Medicine; Notice of Meeting hsrobinson on PROD1PC70 with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the National Advisory Council for Complementary and Alternative Medicine (NACCAM) meeting. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussion could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council for Complementary and Alternative Medicine. Date: February 3, 2006. Closed: 8:30 a.m. to 1 p.m. Agenda: To review and evaluate grant applications and/or proposals. Open: 1:30 p.m. to adjournment. Agenda: The agenda includes opening Remarks by Director, NCCAM, presentations of research results, and other business of the Council. VerDate Aug<31>2005 15:41 Jan 12, 2006 Jkt 208001 Place: Neuroscience Center, 6001 Executive Boulevard, Conference rooms C/D, Bethesda, MD 20892. Contact Person: Richard Nahin, PhD, MPH, Executive Secretary, National Center for Complementary and Alternative Medicine, National Institutes of Health, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, (301) 496–7801. The public comments session is scheduled from 4–4:30 p.m., but could change depending on the actual time spent on each agenda item. Each speaker will be permitted 5 minutes for their presentation. Interested individuals and representatives of organizations are requested to notify Dr. Richard Nahin, National Center for Complementary and Alternative Medicine, NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, Maryland 20892, 301–496–6701, Fax: 301–480–9970. Letters of intent to present comments, along with a brief description of the organization represented, should be received no later than 5 p.m. on January 23, 2006. Only one representative of an organization may present oral comments. Any person attending the meeting who does not request an opportunity to speak in advance of the meeting may be considered for oral presentation, if time permits, and at the discretion of the Chairperson. In addition, written comments may be submitted to Dr. Richard Nahin at the address listed above up to ten calendar days (February 13, 2006) following the meeting. Copies of the meeting agenda and the roster of members will be furnished upon request by contacting Dr. Richard Nahin, Acting Executive Secretary, NACCAM, National Institutes of Health, 6707 Democracy Boulevard, Suite 401, Bethesda, Maryland 20892, 301–496–7801, Fax: 301– 480–9970, or via e-mail at naccames@mail.nih.gov. In the interest of security, NIH has instituted stringent procedures for entrance into the building by nongovernment employees. Persons without a government I.D. will need to show a photo I.D. and signin at the security desk upon entering the building. 2255 provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Complementary and Alternative Medicine Special Emphasis Panel, Training and Education. Date: March 14–15, 2006. Time: 8:30 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Laurie Friedman Donze, PhD, Scientific Review Administrator, Office of Scientific Review, NCCAM, National Institutes of Health, Suite 401, MSC 5475, 6707 Democracy Blvd., Bethesda, MD 20892, (301) 402–1030, donzel@mail.nih.gov. Dated: January 5, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–307 Filed 1–12–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings National Center for Complementary and Alternative Medicine; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel ‘‘Partnerships for Hepatitis C Vaccine Development.’’ Date: January 27, 2006. Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate cooperative agreement applications. Dated: January 5, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy, NIH. [FR Doc. 06–306 Filed 1–12–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 E:\FR\FM\13JAN1.SGM 13JAN1 2256 Federal Register / Vol. 71, No. 9 / Friday, January 13, 2006 / Notices Place: Holiday Inn, Capitol Hill, 550 C Street, SW., Washington, DC 20024. Contact Person: Lucy A. Ward, DVM, PhD, Scientific Review Administrator, Scientific Review Program, Division of Extramural Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892, (301) 594–6635, lward@niaid.nih.gov. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel Units for HIV/AIDS Clinical Trials Network ZAl1–MH–A–M2 (13). Date: January 31, 2006. Time: 11 a.m. to 5 p.m. Agenda: To review and evaluate cooperative agreement applications. Place: National Institutes of Health, Rockledge 6700, 6700B Rockledge Drive, Bethesda, MD 20817, (Telephone Conference Call). Contact Person: Mary J. Homer, PhD, Scientific Review Administrator, Scientific Review Program, National Institute of Allergy and Infectious Diseases, DEA/NIH/DHHS, 6700–B Rockledge Drive, MSC 7616, Room 3147, Bethesda, MD 20892, (301) 496–2550, mjhomer@niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: January 5, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–308 Filed 1–12–06; 8:45 am] Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call). Contact Person: Meenaxi Hiremath, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Blvd., Suite 220, MSC 8401, Bethesda, MD 20892. 301–402–7964. mh392g@nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health, HHS) Dated: January 5, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–309 Filed 1–12–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health BILLING CODE 4140–01–M National Institute on Drug Abuse; Notice of Closed Meetings DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. National Institutes of Health hsrobinson on PROD1PC70 with NOTICES National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commerical property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Hurricane Katrina Time Sensitive Review. Date: January 11, 2006. Time: 12 p.m. to 4 p.m. VerDate Aug<31>2005 15:41 Jan 12, 2006 Jkt 208001 Name of Committee: National Institute on Drug Abuse Initial Review Group, Medication Development Research Subcommittee. Date: March 7–8, 2006. Time: 8:30 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Paul A. Coulis, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on PO 00000 Frm 00079 Fmt 4703 Sfmt 4703 Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Boulevard, Suite 220, Bethesda, MD 20892–8401. 301–443–2105. Name of Committee: National Institute on Drug Abuse Initial Review Group, Health Services Research Subcommittee. Date: March 7–8, 2006. Time: 8:30 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Meenaxi Hiremath, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Blvd., Suite 220, MSC 8401, Bethesda, MD 20892. 301–402–7964. mh392g@nih.gov. Name of Committee: National Institute on Drug Abuse Initial Review Group, Treatment Research Subcommittee. Date: March 7–8, 2006. Time: 9 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Kesinee Nimit, MD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892– 8401. (301) 435–1432. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Member Conflicts. Date: March 7, 2006. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892–8401. 301–402–6626. gm145@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Centers Review Meeting. Date: March 20, 2006. Time: 8:30 a.m. to 11 a.m. Agenda: To review and evaluate grant applications. Place: Ritz-Carlton Hotel, 1700 Tysons Boulevard, McLean, VA 22102. Contact Person: Rita Liu, Ph.D., Associate Director, Office or Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 212, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401. (301) 435–1388. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Program Projects Meeting. Date: March 20, 2006. Time: 12 p.m. to 6 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\13JAN1.SGM 13JAN1

Agencies

[Federal Register Volume 71, Number 9 (Friday, January 13, 2006)]
[Notices]
[Pages 2255-2256]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-308]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel ``Partnerships for Hepatitis C 
Vaccine Development.''
    Date: January 27, 2006.
    Time: 8 a.m. to 6 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.

[[Page 2256]]

    Place: Holiday Inn, Capitol Hill, 550 C Street, SW., Washington, 
DC 20024.
    Contact Person: Lucy A. Ward, DVM, PhD, Scientific Review 
Administrator, Scientific Review Program, Division of Extramural 
Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616, 
Bethesda, MD 20892, (301) 594-6635, lward@niaid.nih.gov.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel Units for HIV/AIDS Clinical Trials 
Network ZAl1-MH-A-M2 (13).
    Date: January 31, 2006.
    Time: 11 a.m. to 5 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, Rockledge 6700, 6700B 
Rockledge Drive, Bethesda, MD 20817, (Telephone Conference Call).
    Contact Person: Mary J. Homer, PhD, Scientific Review 
Administrator, Scientific Review Program, National Institute of 
Allergy and Infectious Diseases, DEA/NIH/DHHS, 6700-B Rockledge 
Drive, MSC 7616, Room 3147, Bethesda, MD 20892, (301) 496-2550, 
mjhomer@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: January 5, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-308 Filed 1-12-06; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.